- Home
- DOYU vs NTHI Comparison
DOYU vs NTHI Comparison
Compare DOYU & NTHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DOYU | NTHI |
|---|---|---|
| Founded | 2014 | 2008 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 153.0M | 178.4M |
| IPO Year | 2019 | N/A |
Fundamental Metrics
Financial Performance| Metric | DOYU | NTHI |
|---|---|---|
| Price | $4.68 | $7.00 |
| Analyst Decision | Hold | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $7.00 | N/A |
| AVG Volume (30 Days) | ★ 27.7K | 27.5K |
| Earning Date | 03-25-2026 | 05-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.28 | $3.20 |
| 52 Week High | $9.34 | $15.50 |
Technical Indicators
Market Signals| Indicator | DOYU | NTHI |
|---|---|---|
| Relative Strength Index (RSI) | 37.19 | 33.02 |
| Support Level | $4.28 | $6.40 |
| Resistance Level | $7.11 | $7.70 |
| Average True Range (ATR) | 0.21 | 0.73 |
| MACD | -0.01 | -0.17 |
| Stochastic Oscillator | 15.91 | 4.29 |
Price Performance
Historical ComparisonAbout DOYU DouYu International Holdings Limited ADS
DouYu International Holdings Ltd is a game-centric live streaming platform in China and a pioneer in the eSports value chain. The company operates its platform on both PC and mobile apps, through which users can enjoy immersive and interactive games and entertainment live streaming. It generates revenues through live streaming and advertisement.
About NTHI NeOnc Technologies Holdings Inc.
NeOnc Technologies Holdings Inc. is the developer of a novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. The company product includes NEO100, which commenced Phase 2a clinical trials, which is used for treating glioblastoma, and has Orphan Drug and Fast Track designation from the United States Food and Drug Administration (FDA).